Newswise — Stanley Chetcuti, M.D., co-author on the Evolut trial of low-risk TAVR/ interventional cardiologist at Michigan Medicine (University of Michigan) comments on importance of both late-breaking clinical trials re: low-risk TAVR (Evolut and Partner 3) at the American College of Cardiology Scientific Sessions.
"This is one of the most groundbreaking days in my career... This shows us clearly the new technology and the available valves are viable options compared to surgery in low-risk patients. We can tell our patients now: If you’re low risk and get a TAVR, you’re going to have outcomes comparable or superior to surgery at one year with less strokes, less death and less hospitalization. More and more of these can be done without general anesthesia, and length of stay will be lower.
"Robust and rigorous follow up is needed to make sure these valves are durable. Additionally, there’s still a need for optimization of pacemaker rates, which some sites, like ours, have already been doing."
New England Journal of Medicine article: https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
Chetcuti's credentials/bio: https://www.umcvc.org/profile/25/stanley-joseph-chetcuti-md